Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD

Respirology

Volumn 13, Issue 7, 2008, Pages 1014-1021

  Chen, Yan ^a   Chen, Ping ^a   Hanaoka, Masayuki ^b   Droma, Yunden ^b   Kubo, Keishi ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Airflow limitation; Airway remodelling; COPD; Cyclooxygenase 2; Matrix metalloproteinase 2; Prostaglandin E2

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE A; PROSTAGLANDIN E3;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPUTUM; WESTERN BLOTTING;

AIRWAY RESISTANCE; ASTHMA; BLOTTING, WESTERN; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPUTUM; TIME FACTORS;

EID: 54349101590     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01365.x     Document Type: Article

References (35)

1. World Health Organization, October 2002. Update 2008: The world health report 2002 - Reducing risks, promoting healthy life. [Accessed 15 July 2008.] Available from URL: http://www.who.int/whr/2002/en/.
2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004 364 : 613 20.
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007 176 : 532 55.
4. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2001 164 : S28 38.
5. Gauvreau GM, Watson RM, O'Byrne PM. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am. J. Respir. Crit. Care Med. 1999 159 : 31 6.
6. DeWitt D, Smith WL. Yes, but do they still get headaches? Cell 1995 83 : 345 8.
7. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000 69 : 145 82.
8. Desouza IA, Franco-Penteado CF, Camargo EA, Lima CS, Teixeira SA et al. Acute pulmonary inflammation induced by exposure of the airways to staphylococcal enterotoxin type B in rats. Toxicol. Appl. Pharmacol. 2006 217 : 107 13.
9. Pavord ID, Tattersfield AE. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995 345 : 436 8.
10. Watkins DN, Garlepp MJ, Thompson PJ. Regulation of the inducible cyclooxygenase pathway in cultured human airway epithelial cells by nitric oxide. Br. J. Pharmacol. 1997 12 : 1482 8.
11. Taha R, Olivenstein R, Utsumi T, Ernst P, Barnes PJ et al. Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000 161 : 636 40.
12. Xaubet A, Roca-Ferrer J, Pujols L, Ramírez J, Mullol J et al. Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2004 21 : 35 42.
13. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000 117 : 684 94.
14. Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venge P et al. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am. J. Respir. Crit. Care Med. 1999 159 : 1985 91.
15. Cataldo D, Munaut C, Noel A, Frankenne F, Bartsch P et al. MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int. Arch. Allergy Immunol. 2000 123 : 259 67.
16. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest. 1998 78 : 1077 87.
17. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T et al. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin. Cancer Res. 2003 9 : 1741 9.
18. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000 60 : 4629 37.
19. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ et al. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res. 2004 64 : 7439 46.
20. World Medical. Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997 277 : 925 6.
21. Pizzichini E, Pizzichini MM, Leigh R, Djukanovic R, Sterk PJ. Safety of sputum induction. Eur. Respir. J. Suppl. 2002 37 : 9s 18s.
22. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur. Respir. J. Suppl. 2002 37 : 19s 23s.
23. Fang X, Chen P, Moore SA. The oxygen radical scavenger pyrrolidine dithiocarbamate enhances interleukin-1beta-induced cyclooxygenase-2 expression in cerebral microvascular smooth muscle cells. Microvasc. Res. 2002 64 : 405 13.
24. Liu H, Mamoon AM, Farley JM Sr. Prostanoids secreted by alveolar macrophages enhance ionic currents in swine tracheal submucosal gland cells. J. Pharmacol. Exp. Ther. 2005 315 : 729 39.
25. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003 58 : 585 8.
26. Montuschi P, Macagno F, Parente P, Valente S, Lauriola L et al. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax 2005 60 : 827 33.
27. Russell RE, Thorley A, Culpitt SV, Dodd S, Donnelly LE et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002 283 : L867 73.
28. Adamson IY, Vincent R, Bakowska J. Differential production of metalloproteinases after instilling various urban air particle samples to rat lung. Exp. Lung Res. 2003 29 : 375 88.
29. Cataldo DD, Gueders MM, Rocks N, Sounni NE, Evrard B et al. Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors. Cell. Mol. Biol. 2003 49 : 875 84.
30. Baraldo S, Bazzan E, Zanin ME, Turato G, Garbisa S et al. Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest 2007 132 : 1733 40.
31. 2 stimulates expression of matrix metalloproteinase 2 in cultured rat mesangial cells. Kidney Int. 1997 51 : 1116 23.
32. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J. Biol. Chem. 2002 277 : 50828 33.
33. Snoeck-Stroband JB, Postma DS, Lapperre TS, Gosman MM, Thiadens HA et al. Airway inflammation contributes to health status in COPD: a cross-sectional study. Respir. Res. 2006 7 : 140.
34. Lapperre TS, Willems LN, Timens W, Rabe KF, Hiemstra PS et al. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD. Chest 2007 131 : 53 9.
35. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS et al. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur. Respir. J. 2005 26 : 835 45.